MVA-BN WEV Equine Encephalitis Vaccine Description
MVA-BN WEV is a prophylactic vaccine candidate against three equine encephalitis viruses (western, eastern, and Venezuelan).
Eastern equine encephalitis virus (EEEV), a mosquito-borne alphavirus, is the cause of one of the most severe arboviral diseases in North America, says the CDC.
The clinical course typically begins as a systemic febrile illness but often progresses to neurologic disease. EEEV neuroinvasive disease is estimated to have a 30% case-fatality rate with approximately half of survivors left with neurologic sequelae.
Using the live virus vaccine platform technology, MVA-BN®, Bavarian Nordic has created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system.
In March 2018, Bavarian Nordic entered a multi-year contract valued at up to $36 million with the U.S. Government to develop MVA-BN WEV. Under this contract, Bavarian Nordic is conducting a Phase 1 clinical trial, which was initiated in October 2019.
Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative therapies against infectious diseases and cancer.
MVA-BN WEV Equine Encephalitis Vaccine Indication
MVA-BN-WEV vaccine candidate is indicated to prevent illness from equine encephalitis viruses.
During 2019, the U.S. experienced the worst outbreak of Eastern equine encephalitis since monitoring of the disease began. According to the U.S Centers for Disease Control and Prevention, 38 cases, including 15 deaths were reported in 2019, compared to an annual average of 7 cases over the past decade. The majority of cases occurred in the northeastern parts of the U.S., where mosquitoes have been found to carry the virus.
MVA-BN WEV Equine Encephalitis Vaccine News
June 8, 2020 – Bavarian Nordic announced topline results from the first-in-human trial of MVA-BN WEV, a prophylactic vaccine candidate against three equine encephalitis viruses (western, eastern and Venezuelan), for which there are currently no preventative vaccines available.
October 8, 2019 – Bavarian Nordic A/S announced the initiation of the first-in-human trial of MVA-BN® WEV, a prophylactic vaccine candidate against the equine encephalitis virus - a rare, but potentially deadly illness. The program, which is funded by the United States Department of Defense (DOD) Joint Project Manager for Chemical, Biological, Radiation, and Nuclear Medical (JPM CBRN Medical) is a multi-year agreement valued up to USD 36 million and aims to develop a vaccine against three separate strains of the equine encephalitis virus, Eastern (EEEV), Venezuelan (VEEV), and Western (WEEV).
MVA-BN WEV Equine Encephalitis Vaccine Clinical Trials
Clinical Trial NCT04131595: Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in 45 Healthy Adult Subjects
- To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.
- Data from the study showed that the vaccine was well-tolerated and immunogenic across all dose groups. Neutralizing antibody responses were observed in all dose groups, with peak levels reached after the second vaccination.
- Responses were detected as early as 2 weeks after the first vaccination in the highest dose group, which also complete seroconversion was observed after the second vaccination.
- The most common vaccine-related adverse event was injection site pain.